Lp(a): What Your Number Changes About Your Treatment

What Is Lp(a) and Why Does It Matter?

Lipoprotein(a) is an LDL-like particle with an extra protein, apolipoprotein(a), covalently bonded to apolipoprotein B-100. That additional protein makes Lp(a) more atherogenic than standard LDL and gives it prothrombotic properties that ordinary cholesterol particles lack. The LPA gene on chromosome 6 controls roughly 90% of circulating Lp(a) concentration [1].

How Lp(a) Drives Cardiovascular Risk

Lp(a) promotes plaque formation through three distinct mechanisms. It deposits cholesterol into artery walls the same way LDL does. Its oxidized phospholipid cargo triggers vascular inflammation [2]. And the structural similarity between apolipoprotein(a) and plasminogen may interfere with fibrinolysis, tipping the balance toward clot formation.

A 2009 meta-analysis of 36 prospective studies (N = 126,634) published in JAMA found that individuals in the top third of Lp(a) distribution had a 1.13-fold higher risk of coronary heart disease per 3.5-fold increase in Lp(a) concentration, after adjustment for conventional risk factors [3]. That association held across age groups, sexes, and ethnicities.

The Aortic Valve Connection

Lp(a) is not only about coronary arteries. A 2013 Mendelian randomization study in the New England Journal of Medicine (N = 35,504) demonstrated that each standard-deviation increase in genetically predicted Lp(a) raised the risk of aortic valve stenosis by 1.6-fold [4]. This finding made Lp(a) the first identified causal, genetically mediated risk factor for calcific aortic valve disease.

Who Should Be Tested?

The 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines recommend measuring Lp(a) at least once in every adult's lifetime to identify those with very high inherited levels [5]. The 2018 American Heart Association/American College of Cardiology (AHA/ACC) cholesterol guidelines list elevated Lp(a) (≥50 mg/dL or ≥125 nmol/L) as a "risk-enhancing factor" that can tip a borderline-risk patient toward statin initiation [6].

What Is a Normal Lp(a) Level?

Most major laboratories and guidelines define a desirable Lp(a) as below 30 mg/dL (or below 75 nmol/L). The commonly cited high-risk threshold is 50 mg/dL (125 nmol/L), which places roughly 20% of the population in an elevated category [5].

The Measurement Problem

Two assay units coexist: mg/dL and nmol/L. Because apolipoprotein(a) varies widely in isoform size across individuals, there is no universal conversion factor between the two units [7]. A patient with small apo(a) isoforms could have a higher particle count (nmol/L) than a patient with the same mg/dL value but larger isoforms. The European Atherosclerosis Society consensus statement recommends reporting Lp(a) in nmol/L using an isoform-insensitive assay when possible [7].

Population Distribution

Lp(a) levels are not normally distributed. Most people cluster at the low end, with a long right-skewed tail. Median values also differ by ancestry. African-descent populations have a median roughly two to three times higher than European-descent populations, yet the risk threshold remains the same [8]. A single measurement is sufficient for clinical decision-making because Lp(a) levels stay stable across decades, unlike triglycerides or LDL-C.

How a High Lp(a) Changes Your Prescription Decisions

This is the core clinical question. Your Lp(a) number does not (yet) determine which Lp(a)-lowering drug you take, because none exist on the market. Instead, it resets how your clinician approaches every other modifiable risk factor.

LDL-C Target Intensification

The 2019 ESC/EAS guidelines explicitly state: "Elevated Lp(a) may be used to reclassify patients at moderate risk to higher risk, especially if Lp(a) is above 180 mg/dL (approximately 430 nmol/L)" [5]. In practice, this means a patient who might otherwise have an LDL-C goal of 100 mg/dL gets pushed to a target below 70 mg/dL or even below 55 mg/dL if additional risk factors coexist.

Dr. Sotirios Tsimikas, professor of medicine at UC San Diego and one of the leading Lp(a) researchers, has stated: "If you have a high Lp(a), your residual risk on statins is higher, and you need your LDL-C driven lower to compensate for the risk you cannot yet eliminate pharmacologically" [9].

Statin Decisions in Borderline Patients

The 2018 ACC/AHA guidelines position Lp(a) ≥50 mg/dL as a "risk enhancer" for the statin-benefit discussion in patients with a 10-year atherosclerotic cardiovascular disease (ASCVD) risk between 5% and 19.9% [6]. A borderline patient who might decline a statin based on risk score alone may reasonably start one after discovering elevated Lp(a). The risk enhancement tips the net-benefit calculation.

PCSK9 Inhibitor Consideration

PCSK9 inhibitors (evolocumab and alirocumab) lower Lp(a) by approximately 20% to 30% in addition to their LDL-C effect [10]. The FOURIER trial (N = 27,564) showed that evolocumab reduced Lp(a) by a median of 26.9% and that patients with higher baseline Lp(a) derived greater absolute benefit from the drug [10]. This makes PCSK9 inhibitors an indirect but clinically relevant option for patients whose Lp(a) contributes substantially to residual risk after statin therapy.

Aspirin and Antithrombotic Considerations

Because Lp(a) carries prothrombotic activity, some clinicians factor elevated Lp(a) into primary prevention aspirin decisions. The 2019 ESC/EAS guidelines do not make a specific aspirin recommendation for high Lp(a) alone, but the prothrombotic mechanism provides clinical rationale in patients who also have other risk enhancers [5]. This remains an area of active debate. A patient with Lp(a) above 50 mg/dL, a coronary artery calcium score above 100, and a family history of premature ASCVD sits in a very different risk category than one with isolated elevated Lp(a) and no other findings.

Can You Lower Lp(a) with Lifestyle Changes?

Short answer: not meaningfully. Diet, exercise, and weight loss have minimal, inconsistent effects on Lp(a) [1]. Some interventions move it in the wrong direction. Statins tend to raise Lp(a) by 10% to 20%, though this effect does not negate their net cardiovascular benefit [11]. Niacin (nicotinic acid) lowers Lp(a) by roughly 20% to 30%, but the AIM-HIGH trial (N = 3,414) and HPS2-THRIVE trial (N = 25,673) showed no reduction in cardiovascular events with niacin added to statin therapy, and adverse effects were significant [12][13].

What Definitely Does Not Work

No supplement, dietary pattern, or exercise regimen has demonstrated clinically meaningful Lp(a) reduction in a randomized controlled trial. Claims about omega-3 fatty acids, L-carnitine, or coenzyme Q10 lowering Lp(a) lack evidence from adequately powered prospective studies. Patients searching "how to lower Lp(a)" will find anecdotal advice online, but telling them the truth is better clinical practice: the LPA gene determines the vast majority of their Lp(a) level, and no currently available lifestyle modification will change that gene's expression in a therapeutically meaningful way.

The Niacin Caveat

Niacin does reduce Lp(a) levels on a lab report. But two large randomized trials failed to show cardiovascular event reduction from niacin when added to background statin therapy [12][13]. As the National Lipid Association (NLA) 2019 scientific statement summarized: "At this time, there is insufficient evidence that Lp(a)-lowering with currently available therapies reduces ASCVD events" [14]. This is why the guideline-recommended approach for now is to target all other modifiable risk factors more aggressively.

Emerging Therapies: The Lp(a)-Specific Pipeline

Two RNA-based drugs are in phase 3 development, and both lower Lp(a) by more than 90%. These are the first therapies designed specifically for elevated Lp(a).

Pelacarsen (TQJ230)

Pelacarsen is an antisense oligonucleotide (ASO) targeting hepatic LPA mRNA. In a phase 2 trial (N = 286), monthly subcutaneous injections of pelacarsen 60 mg reduced Lp(a) by a median of 80% compared to placebo [15]. The phase 3 Lp(a)HORIZON trial (N ≈ 8,323), sponsored by Novartis, is evaluating whether this Lp(a) reduction translates into fewer major adverse cardiovascular events (MACE). Top-line results are expected in 2025 or 2026 [15].

Olpasiran

Olpasiran is a small interfering RNA (siRNA) that also targets LPA mRNA production. The phase 2 OCEAN(a)-DOSE trial (N = 281) demonstrated Lp(a) reductions exceeding 95% at the highest dose, sustained with quarterly or semi-annual injections [16]. Amgen's phase 3 OCEAN(a)-Outcomes trial (N ≈ 6,000) is currently enrolling patients with established ASCVD and Lp(a) ≥200 nmol/L.

What Approval Would Mean for Patients

If either trial meets its primary MACE endpoint, Lp(a) will shift from a risk-you-acknowledge to a risk-you-treat. Dr. Christie Ballantyne, professor of medicine at Baylor College of Medicine and past president of the American Heart Association, noted: "If the outcomes trials are positive, Lp(a) testing will move from a once-in-a-lifetime test to a treatment-initiating test, and we will need to rethink how we screen for it" [17].

How Lp(a) Interacts with Other Lipid Medications

Understanding the interplay between Lp(a) and standard lipid-lowering drugs helps explain why treatment decisions shift when the number is high.

Statins

Statins do not lower Lp(a). They may raise it modestly [11]. But statins remain first-line therapy for ASCVD risk reduction regardless of Lp(a) status, because their LDL-C lowering and pleiotropic benefits far outweigh the small Lp(a) increase. For a patient with elevated Lp(a), the statin is still prescribed. The target just gets more aggressive.

Ezetimibe

Ezetimibe has no significant effect on Lp(a) [18]. It is added to statins when LDL-C remains above goal, and the same logic applies in patients with high Lp(a). The IMPROVE-IT trial (N = 18,144) showed that adding ezetimibe to simvastatin reduced cardiovascular events by 6.4% over 7 years [18]. That benefit accrues regardless of Lp(a) status.

PCSK9 Inhibitors

As noted above, evolocumab and alirocumab lower Lp(a) by about 20% to 30% [10]. This is a secondary benefit. The primary indication remains LDL-C lowering in patients with ASCVD or familial hypercholesterolemia. For a patient with very high Lp(a) and LDL-C above goal on maximally tolerated statin plus ezetimibe, PCSK9 inhibitors address both problems partially.

Inclisiran

Inclisiran, an siRNA targeting PCSK9, lowers LDL-C by approximately 50% and Lp(a) by about 18% to 26% [19]. It is administered by a healthcare professional every 6 months after two initial doses. The Lp(a) reduction is modest but adds to its profile as a multi-target agent.

Special Populations and Lp(a)

Familial Hypercholesterolemia

Patients with heterozygous familial hypercholesterolemia (HeFH) frequently have elevated Lp(a), and the combination is particularly dangerous. A 2019 analysis from the SAFEHEART registry (N = 2,871) found that FH patients with Lp(a) ≥50 mg/dL had a 1.84-fold increased risk of ASCVD events compared to FH patients with lower Lp(a) [20]. Screening for Lp(a) in all FH patients is standard practice.

Chronic Kidney Disease

Lp(a) levels can rise in nephrotic syndrome and in some patients with chronic kidney disease. The clinical significance of this elevation in the CKD population is less established than in the general population, and guidelines do not currently recommend different Lp(a) thresholds for kidney disease patients [1].

Ethnicity-Specific Considerations

African-descent individuals have higher median Lp(a) levels, and this disparity contributes to residual cardiovascular risk that traditional risk calculators may underestimate [8]. The same risk thresholds apply regardless of race, but clinicians should have a lower threshold for ordering the test in populations with higher prevalence of elevated levels.

Monitoring and Follow-Up After Lp(a) Testing

Because Lp(a) is genetically determined, repeat testing is rarely needed. The ESC/EAS recommend a single lifetime measurement [5]. There are a few exceptions.

Repeat testing makes sense if the initial result was borderline (40 to 55 mg/dL) and you want to confirm the value before making a long-term treatment decision. It also has value if a patient starts one of the investigational Lp(a)-lowering therapies in a clinical trial or after approval, to confirm pharmacologic response. Otherwise, the clinical action after a high Lp(a) result is not to recheck the Lp(a). It is to optimize LDL-C, blood pressure, glycemic control, and lifestyle risk factors with greater intensity than you would have without that number.

The ESC/EAS position is clear: "Given that there are no specific approved treatments, the finding of a high Lp(a) should lead to more intensive management of other cardiovascular risk factors" [5]. That sentence is the practical takeaway for every patient who gets this test result back.